Publications by authors named "Jim Doherty"

Claim this Profile
A
AI-based, automated chamber volumetry from gated, non-contrast CT.
Athira J Jacob, Ola Abdelkarim, Salma Zook, Kristian Hay Kragholm, Prantik Gupta, Jim O Doherty

J Cardiovasc Comput Tomogr· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Artificial Intelligence Assistance on Chest CT Interpretation Times: A Prospective Randomized Study.
Basel Yacoub, Akos Varga-Szemes, U Joseph Schoepf, Ismail M Kabakus, Dhiraj Baruah, Jim O' Doherty

AJR Am J Roentgenol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns in patients with advanced (stage III-IV) ovarian cancer in the USA and Europe.
Jennifer P Hall, Jane Chang, Rebecca Moon, Olivia Higson, Katherine Byrne, Jim P Doherty

Future Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Tina Krieger, Isobel Pearson, Judith Bell, Jim Doherty, Paul Robbins

Diagn Pathol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Rohan Parikh, Samantha K Kurosky, Margarita Udall, Jane Chang, Joseph C Cappelleri, Jim P Doherty

Int J Gynecol Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
Margarita Udall, Maria Rizzo, Juliet Kenny, Jim Doherty, SueAnn Dahm

Diagn Pathol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Dong-Wan Kim, Edward B Garon, Aminah Jatoi, Dorothy M Keefe, Mario E Lacouture, Jim P Doherty

Lung Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan.
Ataru Igarashi, Manabu Akazawa, Tatsunori Murata, Toshihiko Taguchi, Alesia Sadosky, Jim Doherty

Clinicoecon Outcomes Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Suresh S Ramalingam, Pasi A Jänne, Tony Mok, Kenneth O'Byrne, Michael J Boyer, Jim P Doherty

Lancet Oncol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating a preference-based index from the Japanese SF-36.
John E Brazier, Shunichi Fukuhara, Jennifer Roberts, Samer Kharroubi, Yosuke Yamamoto, Jim Doherty

J Clin Epidemiol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of pharmacoepidemiology in evaluating prescription drug safety in pediatrics.
Xuemei Luo, Jim Doherty, Joseph C Cappelleri, Karen Frush

Curr Med Res Opin· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is next for pharmacoeconomics and outcomes research in Asia?
Jim Doherty, Isao Kamae, Kenneth K C Lee, Hong Li, Shu-Chun Li

Value Health· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical aspects of designing and conducting pharmacoeconomic studies in Japan.
Jim Doherty, Keiko Sato

Pharmacoeconomics· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis